Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.
about
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy.Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer.Pegylated liposomal doxorubicin in the management of ovarian cancerPegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancerOptimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?Analogies between reading of medical and religious texts.Pegylated liposomal doxorubicin in ovarian cancer.Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer"Conflict-of-interest" and participation in IRB deliberations: an alternative perspective.Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer.High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies.Liposomal doxorubicin in breast cancer.Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer.Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment.Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts.Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer.Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study.Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation study.Skin-mucous membrane disorder and therapeutic effect of pegylated liposomal doxorubicin in recurrent ovarian cancer.
P2860
Q33397131-A1CE895D-7D28-4DC5-ABA5-B1120FAC3056Q33415076-7D572862-C5D4-45E8-A5AC-6D977DCCD5A5Q33521785-1FB0A38D-239C-4EFB-8195-C86396D18EF4Q34187661-18D81921-BC6F-4BCC-BB4B-DA92CA5122CBQ34574145-77BA5AB3-3BA6-419F-A224-D560590DFC71Q35114915-910C542E-206E-4806-8D69-E99C65E6B766Q36488198-DA8AD97A-B9C8-4B0C-8485-4C834D7D3139Q36655809-24F244F2-45EA-485E-BDDF-853AF26C03A0Q36718020-6CE32904-DCD2-4488-9023-3567F93CAF52Q36728989-6E2B3AA5-28A0-4D8E-941F-3787BBC0CDFFQ37079908-EDBE03EC-8824-492D-A3E1-7B0ED992C51CQ37507842-02F58536-B4F7-4824-A48E-C2ACCD0DDD53Q37576349-6EB6EFBE-8376-4316-A29C-D4C59254ABA4Q37608442-253592BB-BCBC-44EF-9F45-596F04CD4DEBQ37765581-70F5C018-1932-4EF3-A76F-55CD072026B8Q37857281-BFA704BC-8C31-47F0-AEC4-57A02ACE5282Q37964713-C88F44C0-3764-4182-8D7D-BAB0CED3E6F2Q37965631-D8F8F641-AF4E-4C7C-9AF2-B6A75757D903Q40395847-689C8586-7C45-4D5C-9FEE-AC1955BA7A05Q44616736-9A6EBE51-C3C5-443F-A8A5-02490EFF21D0Q46845098-E1E93279-85CD-4037-AB03-ECEE54F381A5Q48094287-53FE281A-CCF3-4459-A830-4FBC0E678001
P2860
Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Liposomal doxorubicin in ovari ...... study of single-agent dosages.
@en
Liposomal doxorubicin in ovari ...... study of single-agent dosages.
@nl
type
label
Liposomal doxorubicin in ovari ...... study of single-agent dosages.
@en
Liposomal doxorubicin in ovari ...... study of single-agent dosages.
@nl
prefLabel
Liposomal doxorubicin in ovari ...... study of single-agent dosages.
@en
Liposomal doxorubicin in ovari ...... study of single-agent dosages.
@nl
P2093
P356
P1433
P1476
Liposomal doxorubicin in ovari ...... study of single-agent dosages.
@en
P2093
P304
P356
10.1006/GYNO.2001.6272
P407
P577
2001-08-01T00:00:00Z